Hjem
Camilla Tøndels bilde

Camilla Tøndel

Forsker, post doc/barnenefrolog
  • E-postCamilla.Tondel@uib.no
  • Telefon+47 924 68 362
  • Besøksadresse
    Haukeland Universitetssykehus Laboratoriebygget, 7. etg. Heis øst
  • Postadresse
    Postboks 7804
    5020 Bergen

Camilla Tøndel har siden lisensiering av Fabry-spesifikk behandling i 2001 hatt ansvar for oppfølging av barn og voksne med Fabry sykdom, og disputerte i 2013 på evaluering av nyresykdom og enzymsubstitusjonsbehandling ved Fabry sykdom. Nyrebiopsier og nyrefunksjonsmålinger er et viktig fokus i mange av de forskerinitierte og legemiddelindustriinitierte studiene hun er med på, inkludert GMO-basert tidligfase utprøving. Farmakokinetikk i legemiddelutprøving og som viktig verktøy i evaluering av nyresykdom (iohexol clearance) er sentralt i hennes forskning, likeledes immunologiske mekanismer og behandlingsformer innen ulike organsystem/sykdommer. Som del av styret i NorCRIN (siden 2012) og NorPedMed (siden 2014) jobber hun for økt behandlingsforskning i Norge.

MED09: Fagansvarlig pediatrisk nefrologi og reumatologi

GCP901: ICH-Good Clinical Practice

MEDMET1: ICH-Good Clinical Practice

Vitenskapelig artikkel
  • Vis forfatter(e) 2021. Standardising clinical outcomes measures for adult clinical trials in Fabry disease: A global Delphi consensus. Molecular Genetics and Metabolism. 234-243.
  • Vis forfatter(e) 2021. Pharmacokinetics and Safety of Single-dose Tedizolid Phosphate in Children 2 to <12 Years of Age. The Pediatric Infectious Disease Journal. 317-323.
  • Vis forfatter(e) 2021. Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study. Neurourology and Urodynamics.
  • Vis forfatter(e) 2021. Attack rates amongst household members of outpatients with confirmed COVID-19 in Bergen, Norway: A case-ascertained study. Lancet Regional Health Europe.
  • Vis forfatter(e) 2020. SARS-CoV-2-specific neutralizing antibody responses in Norwegian healthcare workers after the first wave of COVID-19 pandemic: a prospective cohort study. Journal of Infectious Diseases.
  • Vis forfatter(e) 2020. Low birthweight is associated with lower glomerular filtration rate in middle-aged mainly healthy women. Nephrology, Dialysis and Transplantation. 1-8.
  • Vis forfatter(e) 2020. Growth Differentiation Factor 15 in Children with Chronic Kidney Disease and after Renal Transplantation. Disease Markers. 1-8.
  • Vis forfatter(e) 2020. Early Induction of Cross-Reactive CD8+ T-Cell Responses in Tonsils After Live-Attenuated Influenza Vaccination in Children. Journal of Infectious Diseases. 1528-1537.
  • Vis forfatter(e) 2020. Accumulation of Globotriaosylceramide in Podocytes in Fabry Nephropathy Is Associated with Progressive Podocyte Loss. Journal of the American Society of Nephrology. 865-875.
  • Vis forfatter(e) 2019. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model-based pediatric dose estimation. Journal of Pediatric Urology.
  • Vis forfatter(e) 2019. Measurement of renal functional response using iohexol clearance—a study of different outpatient procedures. Clinical Kidney Journal (CKJ). 1-8.
  • Vis forfatter(e) 2019. Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial. Molecular Genetics and Metabolism. 86-94.
  • Vis forfatter(e) 2018. The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease - A systematic literature review by a European panel of experts. Molecular Genetics and Metabolism. 1-12.
  • Vis forfatter(e) 2018. Estimating glomerular filtration rate in children: evaluation of creatinine- and cystatin C-based equations. Pediatric nephrology (Berlin, West). 1-11.
  • Vis forfatter(e) 2017. Renal Function Influences Diagnostic Markers in Serum and Urine: A Study of Guanidinoacetate, Creatine, Human Epididymis Protein 4, and Neutrophil Gelatinase–Associated Lipocalin in Children. The Journal of Applied Laboratory Medicine. 297-308.
  • Vis forfatter(e) 2017. Pathomechanisms of renal Fabry disease. Cell and Tissue Research. 53-62.
  • Vis forfatter(e) 2017. Long-term dose-dependent agalsidase effects on kidney histology in fabry disease. American Society of Nephrology. Clinical Journal. 1470-1479.
  • Vis forfatter(e) 2017. Iohexol plasma clearance in children: validation of multiple formulas and single-point sampling times. Pediatric nephrology (Berlin, West). 1-14.
  • Vis forfatter(e) 2017. Hearing loss in children with Fabry disease. The Journal of Inherited Metabolic Disease (JIMD). 725-731.
  • Vis forfatter(e) 2017. Bedside stereomicroscopy of Fabry kidney biopsies: An easily available method for diagnosis and assessment of sphingolipid deposits. Nephron. 13-21.
  • Vis forfatter(e) 2016. Reaccumulation of globotriaosylceramide in podocytes after agalsidase dose reduction in young Fabry patients. Nephrology, Dialysis and Transplantation. 807-813.
  • Vis forfatter(e) 2016. One Year of Enzyme Replacement Therapy Reduces Globotriaosylceramide Inclusions in Podocytes in Male Adult Patients with Fabry Disease. PLOS ONE.
  • Vis forfatter(e) 2016. Live attenuated influenza vaccine in children induces b-cell responses in tonsils. Journal of Infectious Diseases. 722-731.
  • Vis forfatter(e) 2016. Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times. Pediatric nephrology (Berlin, West). 311-320.
  • Vis forfatter(e) 2015. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: The European Fabry Working Group consensus document. Orphanet Journal of Rare Diseases. 1-10.
  • Vis forfatter(e) 2015. Longevity of B-cell and T-cell responses after live attenuated influenza vaccination in children. Journal of Infectious Diseases. 1541-1549.
  • Vis forfatter(e) 2015. Glomerular filtration rate measured by iohexol clearance: A comparison of venous samples and capillary blood spots. Scandinavian Journal of Clinical and Laboratory Investigation. 710-716.
  • Vis forfatter(e) 2015. Foot process effacement is an early marker of nephropathy in young classic fabry patients without albuminuria. Nephron. 16-21.
  • Vis forfatter(e) 2015. Chronic kidney disease and an uncertain diagnosis of Fabry disease: approach to a correct diagnosis. Molecular Genetics and Metabolism. 242-247.
  • Vis forfatter(e) 2015. Characterization of early disease status in treatment-naive male paediatric patients with fabry disease enrolled in a randomized clinical trial. PLOS ONE.
  • Vis forfatter(e) 2014. Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Reports. 83-90.
  • Vis forfatter(e) 2014. Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease. PLOS ONE.
  • Vis forfatter(e) 2013. Agalsidase Benefits Renal Histology in Young Patients with Fabry Disease. Journal of the American Society of Nephrology. 137-148.
  • Vis forfatter(e) 2012. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. American Society of Nephrology. Clinical Journal. 1591-1597.
  • Vis forfatter(e) 2012. Recommendations on Reintroduction of Agalsidase Beta for Patients with Fabry Disease in Europe, Following a Period of Shortage. JIMD Reports.
  • Vis forfatter(e) 2011. Progressive podocyte injury and globotriaosylceramide (GL-3) accumulation in young patients with Fabry disease. Kidney International. 663-670.
  • Vis forfatter(e) 2010. Monitoring renal function in children with Fabry disease: comparisons of measured and creatinine-based estimated glomerular filtration rate. Nephrology, Dialysis and Transplantation. 1507-1513.
  • Vis forfatter(e) 2010. Modelling the resource implications of managing adults with Fabry disease in Norway favours home infusion. European Journal of Clinical Investigation. 1104-1112.
  • Vis forfatter(e) 2009. The MDRD equation may mask decline of glomerular filtration rate in Fabry patients with normal or nearly normal kidney function. Clinical Nephrology. 118-124.
  • Vis forfatter(e) 2009. Monitoring renal Function in Fabry children: comparisons of measured and creatinine-based estimated Glomerular Filtration Rate. Nephrology, Dialysis and Transplantation. 7 sider.
  • Vis forfatter(e) 2008. Renal biopsy findings in children and adolescents with Fabry disease and minimal albuminuria. American Journal of Kidney Diseases. 767-776.
  • Vis forfatter(e) 2005. Focal and segmental glomerular sclerosis (FSGS) in a man and a woman with Fabry's disease. Clinical Nephrology. 394-401.
  • Vis forfatter(e) 2003. [Intravenous Enzyme Substitution Therapy in Children With Fabry's Disease] . Tidsskrift for Den norske legeforening.
  • Vis forfatter(e) 2002. Behandling av Graves sykdom hos barn og unge. Pediatrisk Endokrinologi. 42-46.
Vitenskapelig foredrag
  • Vis forfatter(e) 2021. Cleared Podocytes and Normal Kidney Function in Classical Fabry Males 15 Years After Start of Enzyme Replacement Therapy at Young Age.
  • Vis forfatter(e) 2019. Fabry Nephropathy: First mRNA-seq Findings from Kidney Biopsies Before and After Enzyme Replacement Therapy.
  • Vis forfatter(e) 2015. Cellular immune responses after live attenuated influenza vaccination in children, a clinical trial.
  • Vis forfatter(e) 2013. Podocytes: Therapeutic Target in Fabry Disease?
  • Vis forfatter(e) 2010. 5 YEARS FOLLOW-UP RENAL BIOPSIES IN PAEDIATRIC AND ADULT FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY.
  • Vis forfatter(e) 2009. Corneal changes in Fabry's disease.
Leserinnlegg
  • Vis forfatter(e) 2013. Small fibre neuropathy in Fabry disease. Journal of Neurology. 917-919.
  • Vis forfatter(e) 2011. Fabry or not Fabry – a question of ascertainment. European Journal of Human Genetics. 1111-1112.
Doktorgradsavhandling
  • Vis forfatter(e) 2020. Estimation and measurement of glomerular filtration rate in children.
  • Vis forfatter(e) 2017. Hereditary renal disease in the Norwegian population, with a focus on Fabry disease.
  • Vis forfatter(e) 2013. Markers of nephropathy in young Fabry disease patients; role of kidney biopsies and functional measurement.
Intervju
  • Vis forfatter(e) 2015. Kreft hos barn og betydning av klinisk utprøving hos barn.
  • Vis forfatter(e) 2015. Har testet medisiner på 400 barn.
  • Vis forfatter(e) 2014. Kampen mot kreft.
  • Vis forfatter(e) 2014. Forskning på legemidler til barn må gjøres i Norge.
  • Vis forfatter(e) 2013. Forskning på medisiner til barn, Ekko .
  • Vis forfatter(e) 2013. Enzyme replacement in Fabry disease.
Programdeltagelse
  • Vis forfatter(e) 2015. Liv og død-serien; Legemiddelutprøving hos barn.
Sammendrag/abstract
  • Vis forfatter(e) 2013. Renal structural-functional relationship (SFR) studies suggest that podocyte GL-3 accumulation predicts urine protein creatinine ratio in Fabry disease (FD) nephropathy (FDN). Molecular Genetics and Metabolism. S68-S69.
  • Vis forfatter(e) 2013. GLOMERULAR FILTRATION RATE (GFR) MEASURED BY IOHEXOL CLEARANCE IN CHILDREN; A COMPARISON BETWEEN VENOUS SAMPLES AND DRIED BLOOD SPOTS. Pediatric nephrology (Berlin, West). 1653-1654.
  • Vis forfatter(e) 2013. A randomized, multicenter, multinational, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms: Baseline demographics and clinical data. Molecular Genetics and Metabolism. S99-S99.
  • Vis forfatter(e) 2012. Mosaicism of Podocyte Involvement in Untreated Females with Fabry Disease. Molecular Genetics and Metabolism. S47-S48.
  • Vis forfatter(e) 2010. RENAL FOLLOW-UP BIOPSIES IN YOUNG MALE FABRY PATIENTS ON ENZYME REPLACEMENT THERAPY. Clinical Therapeutics. S105-S107.
  • Vis forfatter(e) 2009. Monitoring renal Function in Fabry children; estimated or measured glomerular Filtration rate? Molecular Genetics and Metabolism. 74-75.
  • Vis forfatter(e) 2009. Fabry Disease: Unusual Symptoms in two Boys Treated with Lamotrigine and Fabrazyme, Respectively. Clinical Therapeutics. S43-S43.
  • Vis forfatter(e) 2008. Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with Fabry disease and microalbuminuria. Clinical Therapeutics. S42-S42.
Poster
  • Vis forfatter(e) 2020. Systems Analyses of Renal Fabry Transcriptome and Response to Enzyme Replacement Therapy (ERT) Identifies a Cross-Validated and Druggable ERT-Resistant Module.
  • Vis forfatter(e) 2020. Switching from agalsidase alfa to pegunigalsidase alfa for treating Fabry disease: One year of treatment data from BRIDGE, a phase III open label study .
  • Vis forfatter(e) 2020. Switching from Agalsidase Alfa to Pegunigalsidase Alfa for Treating Fabry Disease: One Year of Treatment Data from Bridge, a Phase 3 Open-Label Study.
  • Vis forfatter(e) 2020. Low Birth Weigth Is Associated With Lower Measured Glomerular Filtration Rate In Adult Age.
  • Vis forfatter(e) 2020. Diagnosis of AKI using Iohexol in critically ill children and neonates: preliminary results of the HERO study.
  • Vis forfatter(e) 2019. Prelimenary Results of the Fabry Disease Phase III Open Label Study of Switching from Agalsidase Alfa to Pegunigalsidase Alfa.
  • Vis forfatter(e) 2019. Pegunigalsidase alfa for the treatment of Fabry disease - Phase III open label, switch over study from agalsidase alfa - Preliminary results.
  • Vis forfatter(e) 2019. Once every 4 weeks 2 mg/kg of pegunigalsidase alfa for treating Fabry disease- preliminary result of a phase 3 study.
  • Vis forfatter(e) 2019. New Regimen of Once Every 4 Weeks 2 mg/kg of Pedunigalsidase Alfa for Treating Fabry Disease - Prelimenary Results of a Phase 3 Study.
  • Vis forfatter(e) 2019. Measurement of renal functional response using iohexol clearance.
  • Vis forfatter(e) 2019. Clinical Consequences of Paired Cardiac and Kidney Biopsies in a Treatment Naive Female Fabry Patient with a Classical Mutation and Minor Clnical Symptoms.
  • Vis forfatter(e) 2019. Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa Phase III BALANCE study .
  • Vis forfatter(e) 2019. Accumulation of Globotriaosylceramide in Podocytes (PC) in Fabry Nephropathy Is Associated with Progressive PC Loss.
  • Vis forfatter(e) 2018. SINGLE INTRAVENOUS ACCESS FOR MEASUREMENT OF GLOMERULAR FILTRATION RATE IN CHILDREN AFTER MARKER INJECTION.
  • Vis forfatter(e) 2018. Podocyte structural parameters predict glomerular filtration rate (GFR) loss in male patients with classic Fabry disease.
  • Vis forfatter(e) 2018. KIDNEY-SPECIFIC THERAPEUTIC GOALS FOR FABRY DISEASE BASED ON EUROPEAN EXPERT CONSENSUS RECOMMENDATIONS AND SYSTEMATIC REVIEW OF PUBLISHED EVIDENCE.
  • Vis forfatter(e) 2018. IOHEXOL CLEARANCE IN CHILDREN WITH LOW GFR: COMPARISON OF 24 HOURS SINGLE-POINT GFR AND MULTIPLE-POINT GFR.
  • Vis forfatter(e) 2018. Fabry nephropathy: Transcriptome sequencing of microdissected renal compartments from archival kidney biopsies at baseline, and after 5 & 10 years of enzyme replacement therapy.
  • Vis forfatter(e) 2017. Single-point iohexol plasma clearance in children: validation of multiple formulas and sampling times.
  • Vis forfatter(e) 2017. Simplified Clinical Pre-histologic Scoring Method of Kidney Biopsies in Fabry Disease.
  • Vis forfatter(e) 2017. Podocyte globotriaosylceramide (GL-3) content strongly impacts age-dependent podocyte loss in ERT-naïve male Fabry patients.
  • Vis forfatter(e) 2017. A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from superficial skin capillary endothelium.
  • Vis forfatter(e) 2017. A randomized, phase 3B, open-label, parallel-group study of agalsidase beta in treatment-naive male pediatric patients with Fabry disease without severe symptoms (FIELD study): GL-3 clearance from kidney cells.
  • Vis forfatter(e) 2016. Podocyte Hypertrophy and Globotriaosylceramide (GL-3) Accumulation Are Strong Predictors of Podocyte Loss in Enzyme Replacement Therapy Naïve Male Patients with Fabry Disease.
  • Vis forfatter(e) 2016. Glomerular filtration rate (GFR) strongly influences guanidinoacetic acid (GAA) in plasma and urine.
  • Vis forfatter(e) 2016. GDF-15 in plasma and urine as a marker of kidney function in children .
  • Vis forfatter(e) 2016. Differential response of glomerular parietal epithelial cells and podocytes to enzyme replacement therapy in Fabry nephropathy.
  • Vis forfatter(e) 2015. Podocyte Globotriaosylceramide (GL3) Accumulation in Fabry Disease Is Influenced by Age and Genotype .
  • Vis forfatter(e) 2015. LONG-TERM ENZYME REPLACEMENT THERAPY (ERT) BENEFITS THE GLOMERULI MORE THAN THE VASCULATURE IN YOUNGER FABRY NEPHROPATHY .
  • Vis forfatter(e) 2015. FABRY DISEASE DIAGNOSED IN LIVING DONOR KIDNEY TRANSPLANT BIOPSY.
  • Vis forfatter(e) 2015. DIFFERENTIAL KIDNEY EFFECTS OF HIGH AND LOW ENZYME DOSE IN MALE SIBLINGS TREATED FOR 13 YEARS .
  • Vis forfatter(e) 2014. Renal Biopsies after 6-11 Years of Enzyme Replacement Therapy in 9 Young Classic Fabry Disease Patients.
  • Vis forfatter(e) 2014. Five Children with Fabry Disease and Significant Tissue Damage in Renal Biopsies Despite Normal Clinical Renal Parameters.
  • Vis forfatter(e) 2014. Fabry nephropathy (FN) outcome and the impact of diagnostic kidney biopsies after 10 years enzyme replacement therapy (ERT).
  • Vis forfatter(e) 2014. Enzyme Replacement Therapy (ERT) in Fabry Disease (FD) Reduces Podocyte (PC) Globotriaosylceramide (GL3) Content within a Year (yr).
  • Vis forfatter(e) 2014. Consensus recommendation on Fabry disease diagnosis in adult patients with kidney disease.
  • Vis forfatter(e) 2013. Glomerular filtration rate (GFR) measured by iohexolclearance in children; how many sample points are necessary?
  • Vis forfatter(e) 2013. Glomerular Filtration Rate (GFR) measured by Iohexol Clearance in Children; a comparison between venous samples and dried spots.
  • Vis forfatter(e) 2009. Renal follow-up biopsies in young male Fabry patients on enzyme replacement therapy.
  • Vis forfatter(e) 2008. Renal biopsies in children in Norway 1988-2005: clinical variables, complications and prognosis.
  • Vis forfatter(e) 2008. Formula GFR overestimates Renal Function in Children and Adult Males with Fabry Disease and Stage 1-2 CKD.
  • Vis forfatter(e) 2008. Fabry disease: Unusual symptoms in two male children treated with lamotrigine and fabrazyme, respectively.
Errata
  • Vis forfatter(e) 2016. Erratum to: Iohexol plasma clearance in children: validation of multiple formulas and two-point sampling times (Pediatric Nephrology, (2017), 32, 2, (311-320), 10.1007/s00467-016-3436-z). Pediatric nephrology (Berlin, West). 375-376.
Vitenskapelig oversiktsartikkel/review
  • Vis forfatter(e) 2018. European expert consensus statement on therapeutic goals in Fabry disease. Molecular Genetics and Metabolism. 189-203.

Se fullstendig oversikt over publikasjoner i CRIStin.

Forskergrupper